Market news
Zymeworks completes its Theravance Biopharma acquisition, boosts 2026 revenue guidance, and gains recurring revenue from YUPELRI sales.
Zymeworks (ZYME) said Monday it has completed its acquisition of Theravance Biopharma, adding Yupelr
Zymeworks (ZYME) said late Wednesday it completed its previously announced $929 million acquisition
Zymeworks Inc. remains a Buy, leveraging validated technology, strong price momentum, and upcoming catalysts. Read more on ZYME stock here.
Detailed price information for Ocugen Inc (OCGN-Q) from The Globe and Mail including charting and trades.
Why Zymeworks Stock Is Back in Focus After FDA Approval Zymeworks (ZYME) moved into the spotlight after the FDA approved zanidatamab for first line HER2 positive gastroesophageal adenocarcinoma, putting fresh attention on what this decision might imply for future revenue potential. Against this backdrop, Zymeworks has seen momentum build, with a 30 day share price return of 28.31% and a 90 day gain of 15.44%. The 1 year total shareholder return of 95.49% and very large 3 year total...
Detailed price information for Zymeworks Inc (ZYME-Q) from The Globe and Mail including charting and trades.
Zymeworks stock has delivered very strong returns over the past three years, yet the broader valuation checks currently lean toward the shares looking expensive rather than like a clear bargain. Recent gains and optimism around its HER2-targeting therapy are now being weighed against signals that point to limited valuation cushion at today’s levels. Zymeworks has returned about 301% over the past three years, which puts extra focus on whether recent gains already reflect much of the good...
The FDA approved Jazz Pharma’s Ziihera with chemotherapy, with or without BeOne’s Tevimbra, as an initial treatment for advanced HER2-positive gastroesophageal cancer.
Zymeworks (NASDAQ:ZYME) shares climbed nearly 4. 0% in pre-market trading as investors positioned themselves ahead of an important U.
Detailed price information for Zymeworks Inc (ZYME-Q) from The Globe and Mail including charting and trades.
Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.
Detailed price information for Insmed Inc (INSM-Q) from The Globe and Mail including charting and trades.
VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Wells Fargo Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and fireside chat on September 8 at 3:45 pm Eastern Time (
Zymeworks CEO Kenneth Galbraith speaks about the company’s progress for in Q2 2026 August 25, 2026 U.S. PDUFA target action date for zanidatamab has potential to unlock a $250 million U.S. approval milestone and up to $190 million in potential additional global regulatory milestonesAcquisition of Theravance Biopharma, Inc. expected to close in 2H 2026, adding durable commercial cash flows and expanding Zymeworks' diversified revenue baseContinued advancement of R&D pipeline across wholly-owned a
Detailed price information for Zymeworks Inc (ZYME-Q) from The Globe and Mail including charting and trades.
VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its second quarter 2026 financial results after market close on August 6, 2026. In light of the previously announced proposed acquisition of Theravance Biopharma, Zymeworks has elected not to host a second qu
Zymeworks Inc. (NASDAQ:ZYME) is one of the best small cap stocks to buy with the highest upside potential. Truist lifted the price target on Zymeworks Inc. (NASDAQ:ZYME) to $31 from $28 on July 7 and maintained a Buy rating on the shares. The rating update came as part of a broader research note, with the firm […]
This is the newest page. Registered accounts read further back.